US Biodefense Market Insights Forecasts to 2033

• The Market is Growing at a CAGR of 4.23% from 2023 to 2033
• The US Biodefense Market Size is Expected to hold a significant share by 2033

US Biodefense Market is anticipated to hold a significant share by 2033, Growing at a CAGR of 4.23% from 2023 to 2033.

Market Overview

Biodefense is a measure taken to mitigate biological hazards, lower biological risks, and plan for, respond to, and recover from bio incidents that affect the health of people, animals, plants, or the environment, whether they are unintentional, intentional, or naturally occurring. A purposeful discharge of bacteria, viruses, or other pathogens with the intent to infect people or kill them is known as a bioterrorism attack. Biological agents can proliferate in food, water, or the air. Some are also contagious among individuals. They can be very difficult to find. They take several hours or days to cause disease. Scientists fear that biological weapons might be used to cause smallpox, plague, anthrax, botulism, Ebola, and other hemorrhagic fever viruses. To safeguard public health and safety, governments and organizations throughout the world are spending more in biodefense due to the rise in bioterrorism incidents and the possibility of new and emerging infectious illnesses. To improve research, development, and manufacturing of countermeasures against these deadly dangers, the governments are supporting the biodefense industry with substantial investment.

Report Coverage

This research report categorizes the market for the US biodefense market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the biodefense market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the biodefense market.

Driving Factors

Collaborations between the public and commercial sectors have been essential in developing biodefense solution research, development, and deployment, which has further fueled market expansion. Furthermore, the biodefense market is growing because of policies and favorable regulatory environments that promote investment and innovation. Moreover, the strategy highlighted the administration's goals of expanding foreign vaccination distribution partnerships, advancing the healthcare workforce, and bolstering laboratory safety protocols.

Restraining Factors

The high expenses of biodefense solution research and development are a significant barrier to the biodefense market. Significant funding for studies, clinical trials, and regulatory approvals are needed to develop efficient vaccinations, medications, and detecting methods.

Market Segmentation

The US biodefense market share is classified into product and application.

• The anthrax segment is expected to hold the largest market share through the forecast period.   

The US biodefense market is segmented by product into anthrax, smallpox, botulism, and radiation/nuclear. Among these, the anthrax segment is expected to hold the largest market share through the forecast period. The gram-positive bacterium that causes anthrax is called Bacillus anthracis. It is among the most often utilized weapons in bioterrorism attacks. If anthrax is not treated, the fatality rate is between 80 and 90 percent. Because of its extreme lethality, anthrax poses a serious risk of bioterrorism and highlights the necessity of implementing strong biodefense strategies.

• The hospitals and clinics segment dominates the market with the largest market share over the predicted period.

The US biodefense market is segmented by application into hospitals and clinics, ambulatory care centers, and others. Among these, the hospitals and clinics segment dominated the market with the largest market share over the predicted period. As the main healthcare facilities for the management and treatment of people exposed to biological agents, hospitals and clinics are essential to biodefense preparation and reaction. The hospitals and clinics category is the market leader because these facilities require a strong biodefense infrastructure, which includes specialized equipment, diagnostic instruments, and trained personnel.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US biodefense market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• XOMA Corporation
• Elusys Therapeutics Inc.
• Altimmune, Inc.
• Ichor Medical Systems
• EMERGENT
• Cleveland Biolabs
• Dynavax Technologies
• Bavarian Nordic
• SIGA Technologies.
• Ology Bioservices, Inc. 
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2022, Tembexa is the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox, and EMERGENT has acquired exclusive worldwide rights to it.

Market Segment

This study forecasts revenue at US, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the US biodefense market based on the below-mentioned segments:

US Biodefense Market, By Product

• Anthrax
• Smallpox
• Botulism
• Radiation/nuclear

US Biodefense Market, By Application

• Hospitals and Clinics
• Ambulatory Care Centers
• Others